Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Galm
O
O
Fabry
U
U
Osieka
R
R
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use; D019046:Bone Marrow Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004172:Diplopia / Q000209:etiology; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000473:pathology; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use; D010211:Papilledema / Q000209:etiology; D011559:Pseudotumor Cerebri / Q000139:chemically induced* / Q000150:complications
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide